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Ghrelin, the recently identified endogenous ligand of the GH
secretagogue receptor, is a gut-brain peptide with endocrine,
orexigenic, and gastrointestinal effects. In rodents it in-
creases circulating gastrin and insulin levels, whereas in man
it appears to decrease insulin secretion despite a rise in blood
glucose levels. The aim of the present study was to evaluate
the effects of ghrelin administration on total circulating so-
matostatin (SS), pancreatic polypeptide (PP), and gastrin lev-
els compared with those elicited on insulin, glucose, and GH.
Eight healthy volunteers of normal weight (four women and
four men) were injected with 3.3 g/kg ghrelin or saline after
an overnight fast on 2 different days. Blood was taken every
15 min for 1 h and then every 30 min for 2 h. As expected,
ghrelin injection elicited a prompt GH and glucose increase
with a peak at 30 min and an insulin decrease with a nadir at
60 min. Gastrin concentrations were not modified, whereas
significant rises were observed in both SS (in a biphasic pat-
tern with peaks at 15 and 120 min) and PP (which increased
promptly with a peak at 15 min). A significant negative cor-
relation was found between SS (first peak) and insulin
changes (r0.86; P < 0.01). In conclusion, this study clearly
demonstrates that ghrelin stimulates SS and PP release in
man. Although the underlying mechanisms and biological sig-
nificance of these pharmacological effects remain to be elu-
cidated, a causal relationship between the SS increase and the
insulin changes may be hypothesized. Finally, these findings
strongly support ghrelin’s postulated role in linking the en-
docrine control of energy balance and growth with the reg-
ulation of gastrointestinal functions. (J Clin Endocrinol
Metab 88: 701–704, 2003)
GHRELIN WAS IDENTIFIED and purified from the ratand human stomach in 1999 because of its ability to
bind the GH secretagogue receptor (1). Ghrelin is a gut-brain
hormone, as it is synthesized in the hypothalamus (1), en-
docrine pancreas islets, and gastrointestinal tract (2–4). Al-
though probably able to exert paracrine effects, it is released
in the bloodstream from the gastric-enteric source, and most
of its actions are believed to be due to endocrine effects (1).
In analogy with synthetic GH secretagogues, ghrelin pos-
sesses powerful and dose-dependent GH-releasing activity,
although its physiological role in GH secretion is probably
less important than first believed (4). In the circulation,
ghrelin levels mostly change in relation to the nutritional
intake (5), thus suggesting a primary role in the regulation
of food intake and absorption (6). In fact, it has been shown
that ghrelin has orexigenic effects in both the rat and man,
increasing food intake and fat deposition (7, 8). Moreover, in
the rat, it modulates gastric motility and acid secretion (9, 10),
inhibits gastric emptying (9), and increases insulin and gas-
trin secretion (11). All of these findings suggest important
links with gastro-entero-pancreatic (GEP) hormones. In man,
surprisingly, a decrease in insulin levels and an increase in
glucose concentrations have been reported after ghrelin ad-
ministration (12), whereas no data are as yet available on
possible effects on other GEP hormones. Therefore, the aim
of this study was to evaluate the effects of ghrelin admin-
istration on circulating levels of gastrin, somatostatin (SS),
and pancreatic polypeptide (PP) compared with those elic-
ited on GH, insulin, and glucose concentrations in healthy
human subjects.
Subjects and Methods
Subjects
Eight healthy subjects of normal weight recruited among medical
staff (four men and four women; mean age, 30  9 yr; mean body mass
index, 22  2 kg/m2) volunteered for this study, which was approved
by the local ethics committee. All subjects had normal physical exam-
ination and no history of gastrointestinal or endocrine disorders.
Procedures
After an overnight fast, an iv catheter was inserted in a forearm vein
between 0800 and 0900 h and was kept patent by slow saline infusion.
After 1 h of bed rest, all subjects were injected with either human ghrelin
(Europeptides, Argenteuil, France) at a dose of 3.3 g/kg as an iv bolus
at time zero or saline; the two tests were performed in random order on
different occasions at least 7 d apart. This pharmacological ghrelin dose
was chosen because it has previously been shown to be effective in
eliciting GH release in humans (13), and in our hands it induced ghrelin
peaks ranging from 1967 to 4933 pmol/liter. Blood samples were taken
at –30, 0, 15, 30, 45, 60, 90, 120, 150, and 180 min. Plasma samples for SS,
PP, and gastrin assays were collected in ice-chilled polypropylene tubes
containing EDTA (1 mg/ml) and aprotinin (500 kallikrein inhibitory
units/ml), immediately separated by centrifugation at 4 C, and stored
at –80 C until assayed. Serum for GH, ghrelin, and insulin and plasma
for glucose were separated at room temperature and stored at –20 C.
Methods
Plasma SS and PP levels were measured after extraction on Sep-Pak
C18 cartridges by RIA kits (Peninsula Laboratories, Inc., Belmont, CA)
(14). The antibody employed for SS measurement bound equally well
SS-14 and SS-28 (15); thus, total SS-like immunoreactivity was measured.
Abbreviations: AUC, Area under the curve; GEP, gastro-entero-
pancreatic; NPY, neuropeptide Y; PP, pancreatic polypeptide; SS,
somatostatin.
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Plasma gastrin concentrations were assayed using a RIA kit (DiaSorin,
Inc., Stillwater, MN).
Serum GH levels were measured by IFMA (AutoDelfia kit, Wallac,
Inc. OY, Turku, Finland), serum insulin by ELISA (Medgenix-Ins-
EASIA, Biosource Technologies, Inc. Europe, Nivelles, Belgium), and
plasma glucose levels by glucose autoanalyzer with hexokinase method
(Beckman, Milan, Italy). Ghrelin was assayed by RIA (Phoenix Phar-
maceuticals, Inc., Belmont, CA) as previously described (16). The intra-
and interassay coefficients of variation were less than 10% for all
methods.
Statistical analysis
Statistical analysis was carried out using Friedman’s test, followed by
the Wilcoxon matched pairs test with Bonferroni’s correction for mul-
tiple comparisons. The area under the curve (AUC) was calculated by
trapezoidal integration, and comparison between AUCs was made using
paired t test. Correlations were calculated by linear regression analysis.
The results were expressed as the mean  sd unless otherwise stated
(Fig. 1). P  0.05 was considered statistically significant.
Results
Saline
Mean serum GH and insulin levels and plasma SS, PP, and
gastrin levels did not change significantly after saline ad-
ministration (Fig. 1).
Ghrelin
The results are shown in Fig. 1. As expected, ghrelin elic-
ited a marked GH rise with a peak of 53  23 g/liter at 30
min (P  0.01), a significant decrease in insulin concentra-
tions from 41.6  21.5 to a nadir of 24.4  13.6 pmol/liter at
60 min (P  0.05), and a significant increase in glucose con-
centrations from 4.7  0.2 to 5.1  0.3 mmol/liter at 30 min
(P  0.05). Also, SS concentrations rose significantly, with a
biphasic pattern. Namely, a first smaller peak (from 14  6
to 21 6 ng/liter; P 0.05) was observed at 15 min, followed
by a second, higher peak of 29 11 ng/liter (P 0.05) at 150
min. The mean integrated concentrations of plasma SS were
significantly higher after ghrelin than after saline (ghrelin
AUC, 3876 1069; saline AUC, 1542 361 ng/liter180 min;
P  0.01). PP levels rose in all patients by about 3-fold, from
15.5 5.3 to 51 20.3 pmol/liter (P 0.01) at 15 min (ghrelin
AUC, 4905  1922; saline AUC, 1230  677 pmol/liter180
min; P  0.005). On the contrary, gastrin levels were not
modified by ghrelin administration (ghrelin AUC, 7649 
1379; saline AUC, 7735 1783 ng/liter180 min). A negative
correlation was observed between the changes in SS, first
peak, and insulin levels (r  0.86; P  0.01).
Discussion
The present study demonstrates for the first time that
under fasting conditions in man, ghrelin stimulates SS and
PP release, whereas it does not modify circulating gastrin
levels. In addition, it confirms that ghrelin has an inhibitory
effect on insulin release despite increasing blood glucose
concentrations (12). In this respect it is intriguing that both
insulin and SS have an inhibitory effect on ghrelin secretion
(17), suggesting complex interactive loops whose physiolog-
ical significance remains to be clarified. The ghrelin-induced
SS rise shows a biphasic pattern of response, and it is note-
worthy that the first increase in SS correlated negatively with
the decrease in insulin. Thus, it may be hypothesized that the
initial SS release accounts for the subsequent decrease in
insulin concentrations. This interpretation is in keeping with
the recent finding by Broglio et al. (18) that combined ghrelin
and SS administration produces no additive effect on the
insulin decrease compared with individual treatments.
Moreover, it is well known that SS inhibits insulin release and
FIG. 1. Pattern of blood levels of GH, PP, gastrin, SS, insulin, and glucose after iv administration of ghrelin (3.3 g/kg; filled symbols) or saline
(open symbols), at time zero. Data are the mean  SEM. *, P  0.05; **, P  0.01.
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increases glucose concentrations (19). This suggests that even
the glucose increase may be related to the SS rise. However,
this hypothesis is not very consistent with the time course of
glucose modifications that occurred simultaneously with
those of SS, with a peak observed before any significant
insulin decrease.
Therefore, it is conceivable that ghrelin itself has a direct,
to date unknown, effect on glucose metabolism (by promot-
ing glycogen breakdown or decreasing peripheral glucose
uptake). Consistent with this view are the findings that
ghrelin receptors are expressed in normal human liver (20,
21), and that in hepatoma cells, ghrelin has been shown
to up-regulate gluconeogenesis (20), suggesting a role for
ghrelin in regulating hepatic glucose metabolism. Alterna-
tively, an indirect ghrelin effect on glucose could result from
its influence on other hormone release. Thus, an increase in
circulating epinephrine concentrations has been described to
occur 10 min after ghrelin injection in man (22) and could
cause the glucose increase. Also, the ghrelin-induced cortisol
rise (4, 23) could play a role.
In the present study total SS immunoreactivity was mea-
sured by an antibody that recognizes both SS-14 and SS-28
with equal affinity (15). It is known that in man SS-28 is
mainly released by the small intestine and is the predominant
form of circulating SS both in the fasting state and after a meal
(15, 24), but further studies are needed to clarify which form
of SS is stimulated by ghrelin.
Ghrelin could elicit the first SS rise through different mech-
anisms. Both a direct effect on GEP D cells and indirect
effects, mediated by vagal or -adrenergic stimulation, may
be hypothesized. In favor of the first hypothesis is the ob-
servation that in man, in contrast to rats, a relatively large
number of D cells are present in oxyntic glands in close
proximity with X/A-like, ghrelin-producing cells (25). In
addition, as GH secretogogue receptors are expressed in the
pancreas (26), ghrelin could directly stimulate D cells of the
pancreatic islets in man. Consistent with a role of vagal tone,
there are the observations that circulating SS levels are partly
dependent upon vagal tone (27) and that ghrelin adminis-
tration activates the neurons of the solitary tract and dorso-
motor nucleus of the vagus (10), although there is evidence
that some endocrine ghrelin actions are independent of cho-
linergic mediation (28). Finally, as ghrelin administration
elicits an increase in circulating epinephrine levels, and -
adrenergic fibers stimulate SS release in perfused human
pancreas (29), the activation of -adrenergic receptors could
also play a role.
The second SS peak could be the consequence of the im-
portant elevation of GH elicited by ghrelin administration. In
fact, the observations that acromegalic patients tend to have
higher fasting SS levels than healthy subjects (30) and that
non-GH-deficient children treated with GHRH have in-
creased plasma SS levels (31) support the hypothesis that GH
itself might cause the increase in circulating SS levels, with
a GEP source, besides increasing hypothalamic SS (32).
The powerful stimulating effect of ghrelin on PP release
may be to some extent caused by vagal stimulation. In fact,
vagal cholinergic mechanisms play the major role in the
control of PP release (33). PP is a member of a brain-gut
peptides family that also includes neuropeptide Y (NPY),
with which it shares strong structural homology (34). It is
well known that the stimulation of NPY is one of the mech-
anisms by which ghrelin stimulates appetite at the central
level, at least in the rat (1, 6). Therefore, it is of interest that
ghrelin is also a powerful stimulant of the pancreatic ho-
molog of NPY. The genes encoding for these peptides have
arisen from a common ancestral gene (34). It has been ob-
served that ghrelin has direct activating effects on NPY genes
in the arcuate nucleus (4). Thus, it might be worthwhile
investigating whether ghrelin also has effects on pancreatic
genes encoding PP. In rodents, PP participates in the control
of food intake and gastric motility. When administered pe-
ripherally or when present in the circulation at high levels,
such as in PP transgenic mice, PP decreases food intake and
body weight (35, 36). PP and ghrelin could participate in a
homeostatic loop that controls adaptive responses to star-
vation and the development of obesity.
In conclusion, the present study clearly demonstrates that
ghrelin is able to stimulate some GEP hormone release in
man. The underlying mechanisms and the biological signif-
icance of these effects remain to be elucidated. However, our
findings strongly support and extend the role of ghrelin in
linking the endocrine control of energy balance and growth
with the regulation of gastrointestinal functions.
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